Management

Management of ALSP:
•    Clinical Approach:
A multidisciplinary team approach is recommended for comprehensive care, with treatment strategies tailored to the patient's specific symptomatic manifestations.

•    Long-term Follow-up:
Ongoing patient monitoring should be coordinated by a neurologist specializing in neurodegenerative disorders or a neurogenetics expert.

•    Key Management Focus Areas:
a) Monitoring neurological symptom progression
b) Early identification of cognitive decline
c) Assessment of motor dysfunction (including parkinsonian features and spasticity)
d) Early detection and intervention for psychiatric/behavioral abnormalities
e) Regular neuroimaging evaluations (MRI)
f) Swallowing function surveillance (aspiration pneumonia prevention)
g) Nutritional status assessment
h) Management of autonomic dysfunction (e.g., urinary incontinence)

•    Important Considerations:
Currently, no disease-modifying therapies are available. Management primarily focuses on symptomatic control and quality of life maintenance.

Genetic Counseling:
ALSP follows an autosomal dominant inheritance pattern caused by pathogenic variants in the CSF1Rgene. If the identified variant occurred de novo in the proband (i.e., not detected in either parent), the recurrence risk for future pregnancies of the parents is <1%.

For families with a known CSF1Rpathogenic variant:
a) Each child of an affected individual has a 50% chance of inheriting the mutation.
b) Prenatal diagnosis (via chorionic villus sampling or amniocentesis) and preimplantation genetic testing (PGT) are available for at-risk pregnancies.